The All India Drug Action Network stated that it was “baffled to understand what scientific logic has motivated the relevant oversight committee

The All India Drug Action Network stated that it was “baffled to understand what scientific logic has motivated” the relevant oversight committee to approve “an incompletely studied vaccine.” The medical group asserted that the lack of transparency and hasty approval “raises more questions than answers and likely will not reinforce faith in our scientific decision-making bodies.” Dr Gagandeep Kang, one of India's most distinguished medical experts, told the Times of India that she had "not seen anything like this before", and pointed out: “There is absolutely no efficacy data that has been presented or published.” Meanwhile, Indian MP Shashi Tharoor was among those who posted on Twitter to share their reservations. “The Covaxin has not yet had Phase 3 trials. Approval was premature and could be dangerous. @drharshvardhan should please clarify. Its use should be avoided till full trials are over. India can start with the AstraZeneca vaccine in the meantime,” he wrote. India's Drugs Controller General, VG Somani, said that Covaxin was “safe and provides a robust immune response.”